Vertex Pharmaceuticals Inc
VRTX462.900USD
-0.090-0.02%
終値 12/26, 16:00（ET）15分遅れの株価
117.55B時価総額
32.35直近12ヶ月PER
詳細情報 Vertex Pharmaceuticals Inc 企業名
Vertex Pharmaceuticals Incorporated is a global biotechnology company that invests in scientific innovation to create transformative medicines for people with serious diseases, with a focus on specialty markets. It has seven approved medicines: five that treat the underlying cause of cystic fibrosis (CF), one that treats severe sickle cell disease (SCD) and transfusion dependent beta thalassemia (TDT), and one that treats moderate-to-severe acute pain. Its pipeline includes clinical-stage programs in CF, SCD, beta thalassemia, acute and peripheral neuropathic pain, APOL1-mediated kidney disease, IgA nephropathy and other autoimmune renal diseases and cytopenias, type 1 diabetes, myotonic dystrophy type 1, and autosomal dominant polycystic kidney disease. Its marketed medicines are TRIKAFTA/KAFTRIO (elexacaftor/tezacaftor/ivacaftor and ivacaftor), SYMDEKO/SYMKEVI (elexacaftor/tezacaftor/ivacaftor and ivacaftor), ORKAMBI (lumacaftor/ivacaftor), and KALYDECO (ivacaftor).
Vertex Pharmaceuticals Incの企業情報
企業コードVRTX
会社名Vertex Pharmaceuticals Inc
上場日Jul 24, 1991
最高経営責任者「CEO」Kewalramani (Reshma)
従業員数6100
証券種類Ordinary Share
決算期末Jul 24
本社所在地50 Northern Avenue
都市BOSTON
証券取引所NASDAQ OMX - NASDAQ BASIC
国United States of America
郵便番号02210
電話番号16173416393
ウェブサイトhttps://www.vrtx.com/
企業コードVRTX
上場日Jul 24, 1991
最高経営責任者「CEO」Kewalramani (Reshma)
Vertex Pharmaceuticals Incの経営陣
会社名
会社名/ポジション
ポジション
株式保有
変動額
Dr. Reshma Kewalramani
Dr. Reshma Kewalramani
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
51.81K
+23.92%
Mr. Bruce I. Sachs
Mr. Bruce I. Sachs
Lead Independent Director
Lead Independent Director
45.00K
+12.50%
Dr. Carmen Bozic, M.D.
Dr. Carmen Bozic, M.D.
Executive Vice President - Global Medicines Development and Medical Affairs, Chief Medical Officer
Executive Vice President - Global Medicines Development and Medical Affairs, Chief Medical Officer
32.67K
+40.46%
Dr. Ourania (Nia) Tatsis, Ph.D.
Dr. Ourania (Nia) Tatsis, Ph.D.
Executive Vice President, Chief Regulatory and Quality Officer
Executive Vice President, Chief Regulatory and Quality Officer
25.80K
-14.85%
Dr. Jeffrey M. (Jeff) Leiden, M.D., Ph.D.
Dr. Jeffrey M. (Jeff) Leiden, M.D., Ph.D.
Executive Chairman of the Board
Executive Chairman of the Board
24.47K
--
Mr. Duncan Mckechnie
Mr. Duncan Mckechnie
Executive Vice President, Chief Commercial Officer
Executive Vice President, Chief Commercial Officer
16.13K
--
Mr. Jonathan Biller, J.D.
Mr. Jonathan Biller, J.D.
Executive Vice President, Chief Legal Officer
Executive Vice President, Chief Legal Officer
15.31K
-2.22%
Mr. Lloyd A. Carney
Mr. Lloyd A. Carney
Independent Director
Independent Director
6.32K
-11.24%
Dr. Sangeeta N. Bhatia, M.D., Ph.D.
Dr. Sangeeta N. Bhatia, M.D., Ph.D.
Independent Director
Independent Director
4.57K
-5.51%
Ms. Jennifer J. Schneider
Ms. Jennifer J. Schneider
Independent Director
Independent Director
1.72K
+86.33%
詳細を見る
会社名
会社名/ポジション
ポジション
株式保有
変動額
Dr. Reshma Kewalramani
Dr. Reshma Kewalramani
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
51.81K
+23.92%
Mr. Bruce I. Sachs
Mr. Bruce I. Sachs
Lead Independent Director
Lead Independent Director
45.00K
+12.50%
Dr. Carmen Bozic, M.D.
Dr. Carmen Bozic, M.D.
Executive Vice President - Global Medicines Development and Medical Affairs, Chief Medical Officer
Executive Vice President - Global Medicines Development and Medical Affairs, Chief Medical Officer
32.67K
+40.46%
Dr. Ourania (Nia) Tatsis, Ph.D.
Dr. Ourania (Nia) Tatsis, Ph.D.
Executive Vice President, Chief Regulatory and Quality Officer
Executive Vice President, Chief Regulatory and Quality Officer
25.80K
-14.85%
Dr. Jeffrey M. (Jeff) Leiden, M.D., Ph.D.
Dr. Jeffrey M. (Jeff) Leiden, M.D., Ph.D.
Executive Chairman of the Board
Executive Chairman of the Board
24.47K
--
Mr. Duncan Mckechnie
Mr. Duncan Mckechnie
Executive Vice President, Chief Commercial Officer
Executive Vice President, Chief Commercial Officer
16.13K
--
収益内訳
通貨: USD更新時刻: Mon, Oct 6
通貨: USD更新時刻: Mon, Oct 6
FY2025Q2
FY2025Q1
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2022Q3
FY2022Q2
FY2022Q1
FY2021
FY2020
FY2019
FY2018
事業別USD
会社名
収益
比率
TRIKAFTA
2.55B
86.65%
Other product revenues
205.70M
6.99%
ALYFTREK
156.80M
5.33%
CASGEVY
30.40M
1.03%
地域別USD
会社名
収益
比率
United States
1.83B
62.08%
Europe
910.90M
30.94%
Other
205.60M
6.98%
事業別
地域別
事業別USD
会社名
収益
比率
TRIKAFTA
2.55B
86.65%
Other product revenues
205.70M
6.99%
ALYFTREK
156.80M
5.33%
CASGEVY
30.40M
1.03%
株主
更新時刻: Sat, Nov 15
更新時刻: Sat, Nov 15
株主統計
種類
株主統計
株主統計
比率
Capital World Investors
10.21%
The Vanguard Group, Inc.
9.50%
Capital Research Global Investors
6.52%
BlackRock Institutional Trust Company, N.A.
5.70%
State Street Investment Management (US)
4.57%
他の
63.49%
株主統計
株主統計
比率
Capital World Investors
10.21%
The Vanguard Group, Inc.
9.50%
Capital Research Global Investors
6.52%
BlackRock Institutional Trust Company, N.A.
5.70%
State Street Investment Management (US)
4.57%
他の
63.49%
種類
株主統計
比率
Investment Advisor
60.07%
Investment Advisor/Hedge Fund
28.01%
Research Firm
2.35%
Pension Fund
2.27%
Bank and Trust
2.08%
Sovereign Wealth Fund
1.50%
Hedge Fund
1.14%
Individual Investor
0.14%
Insurance Company
0.09%
他の
2.35%
機関投資家保有株
更新時刻: Wed, Oct 1
更新時刻: Wed, Oct 1
報告期間
機関投資家数
保有株式数
比率
変動額
2025Q3
2933
249.27M
98.24%
-2.14M
2025Q2
2933
252.71M
98.56%
+2.47M
2025Q1
2977
252.24M
98.22%
-39.54K
2024Q4
2877
248.76M
96.87%
-2.25M
2024Q3
2786
247.87M
96.18%
-4.19M
2024Q2
2747
248.36M
96.27%
-4.14M
2024Q1
2680
247.63M
95.87%
-4.48M
2023Q4
2608
247.92M
96.20%
-4.51M
2023Q3
2477
248.64M
96.45%
-6.19M
2023Q2
2488
248.89M
96.55%
-7.11M
詳細を見る
株主動向
会社名
保有株式数
比率
変動額
変動率
日付
Capital World Investors
28.73M
11.21%
+198.84K
+0.70%
Jun 30, 2025
The Vanguard Group, Inc.
23.86M
9.31%
+479.23K
+2.05%
Jun 30, 2025
Capital Research Global Investors
16.11M
6.28%
+1.57M
+10.81%
Jun 30, 2025
BlackRock Institutional Trust Company, N.A.
14.15M
5.52%
+156.31K
+1.12%
Jun 30, 2025
State Street Investment Management (US)
11.78M
4.59%
-13.43K
-0.11%
Jun 30, 2025
Geode Capital Management, L.L.C.
5.93M
2.31%
+166.99K
+2.90%
Jun 30, 2025
Invesco Capital Management (QQQ Trust)
5.26M
2.05%
-18.59K
-0.35%
Aug 31, 2025
Wellington Management Company, LLP
4.81M
1.88%
-641.36K
-11.76%
Jun 30, 2025
Capital International Investors
2.64M
1.03%
+1.99M
+305.59%
Jun 30, 2025
AllianceBernstein L.P.
4.38M
1.71%
+424.81K
+10.75%
Jun 30, 2025
詳細を見る
関連ETF
更新時刻: Fri, Dec 5
更新時刻: Fri, Dec 5
銘柄名
比率
VanEck Biotech ETF
9.71%
ProShares Ultra Nasdaq Biotechnology
8.83%
Invesco Nasdaq Biotechnology ETF
8.76%
iShares Biotechnology ETF
7.43%
Invesco Biotechnology & Genome ETF
5.35%
Natixis Loomis Sayles Focused Growth ETF
4.48%
First Trust NASDAQ Pharmaceuticals ETF
4.23%
First Trust NYSE Arca Biotechnology Index Fund
3.5%
Franklin Genomic Advancements ETF
3.33%
Simplify Health Care ETF
3.25%
詳細を見る
VanEck Biotech ETF
比率9.71%
ProShares Ultra Nasdaq Biotechnology
比率8.83%
Invesco Nasdaq Biotechnology ETF
比率8.76%
iShares Biotechnology ETF
比率7.43%
Invesco Biotechnology & Genome ETF
比率5.35%
Natixis Loomis Sayles Focused Growth ETF
比率4.48%
First Trust NASDAQ Pharmaceuticals ETF
比率4.23%
First Trust NYSE Arca Biotechnology Index Fund
比率3.5%
Franklin Genomic Advancements ETF
比率3.33%
Simplify Health Care ETF
比率3.25%
配当金
過去5年間の配当金総支払額は
0.00
米ドルである。
日付
配当金
権利確定日
支払日
配当落ち日
データなし
株式分割
日付
種類
比率
データなし
日付
種類
比率
データなし
よくある質問
Vertex Pharmaceuticals Incの上位5名の株主は誰ですか？
Vertex Pharmaceuticals Incの上位5名の株主は以下のとおりです。
Capital World Investorsは28.73M株を保有しており、これは全体の11.21%に相当します。
The Vanguard Group, Inc.は23.86M株を保有しており、これは全体の9.31%に相当します。
Capital Research Global Investorsは16.11M株を保有しており、これは全体の6.28%に相当します。
BlackRock Institutional Trust Company, N.A.は14.15M株を保有しており、これは全体の5.52%に相当します。
State Street Investment Management (US)は11.78M株を保有しており、これは全体の4.59%に相当します。
Capital World Investorsは28.73M株を保有しており、これは全体の11.21%に相当します。
The Vanguard Group, Inc.は23.86M株を保有しており、これは全体の9.31%に相当します。
Capital Research Global Investorsは16.11M株を保有しており、これは全体の6.28%に相当します。
BlackRock Institutional Trust Company, N.A.は14.15M株を保有しており、これは全体の5.52%に相当します。
State Street Investment Management (US)は11.78M株を保有しており、これは全体の4.59%に相当します。
Vertex Pharmaceuticals Incの株主タイプ上位3種は何ですか？
Vertex Pharmaceuticals Incの株主タイプ上位3種は、
Capital World Investors
The Vanguard Group, Inc.
Capital Research Global Investors
Capital World Investors
The Vanguard Group, Inc.
Capital Research Global Investors
Vertex Pharmaceuticals Inc（VRTX）の株式を保有している機関の数はいくつですか？
2025Q3時点で、Vertex Pharmaceuticals Incの株式を保有している機関は2933社あり、保有株式の総市場価値は約249.27Mで、全体の98.24%を占めています。2025Q2と比較して、機関の持ち株は-0.32%増加しています。
Vertex Pharmaceuticals Incの最大の収益源は何ですか？
FY2025Q2において、TRIKAFTA部門がVertex Pharmaceuticals Incにとって最大の収益を生み出しており、その金額は2.55Bで、全収益の86.65%を占めています。
